Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study

Table 3 Comparison of platelet counts at baseline and post-treatment in the different platelet count groups

	Baseline (× 109/L)	Post-treatment (× 109/L)	Change (× 109/L)	P value1
Group I (n = 25)				< 0.001
mean ± SD	21.60 ± 7.22	68.28 ± 57.52	46.68 ± 56.77
Median	21.00	55.00	35.00
IQR	16.50-28.00	30.50-82.50	4.50-56.50
Min, max	6.00, 30.00	7.00, 235.00	-4.00, 214.00
Group II (n = 43)				< 0.001
mean ± SD	41.19 ± 5.81	96.23 ± 80.58	55.05 ± 79.80
Median	41.00	76.00	35.00
IQR	35.00-46.00	54.00-133.00	12.00-93.00
Min, max	31.00, 50.00	9.00, 489.00	-31.00, 448.00
Group III (n = 32)				< 0.001
mean ± SD	61.78 ± 8.28	141.53 ± 86.99	79.75 ± 87.04
Median	61.00	127.50	70.00
IQR	55.00-67.00	53.25-214.25	-4.75-146.50
Min, max	51.00, 86.00	7.00, 307.00	-53.00, 255.00

¹Wilcoxon rank sum test.